Nature Communications (Apr 2020)
Timing the initiation of multiple myeloma
- Even H. Rustad,
- Venkata Yellapantula,
- Daniel Leongamornlert,
- Niccolò Bolli,
- Guy Ledergor,
- Ferran Nadeu,
- Nicos Angelopoulos,
- Kevin J. Dawson,
- Thomas J. Mitchell,
- Robert J. Osborne,
- Bachisio Ziccheddu,
- Cristiana Carniti,
- Vittorio Montefusco,
- Paolo Corradini,
- Kenneth C. Anderson,
- Philippe Moreau,
- Elli Papaemmanuil,
- Ludmil B. Alexandrov,
- Xose S. Puente,
- Elias Campo,
- Reiner Siebert,
- Herve Avet-Loiseau,
- Ola Landgren,
- Nikhil Munshi,
- Peter J. Campbell,
- Francesco Maura
Affiliations
- Even H. Rustad
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Venkata Yellapantula
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Daniel Leongamornlert
- The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute
- Niccolò Bolli
- Department of Oncology and Hemato-Oncology, University of Milan
- Guy Ledergor
- Division of Hematology/Oncology, Department of Medicine, University of California
- Ferran Nadeu
- Patologia Molecular de Neoplàsies Limfoides, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
- Nicos Angelopoulos
- The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute
- Kevin J. Dawson
- The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute
- Thomas J. Mitchell
- The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute
- Robert J. Osborne
- The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute
- Bachisio Ziccheddu
- Department of Oncology and Hemato-Oncology, University of Milan
- Cristiana Carniti
- Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Vittorio Montefusco
- Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori
- Paolo Corradini
- Department of Oncology and Hemato-Oncology, University of Milan
- Kenneth C. Anderson
- Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Harvard Medical School
- Philippe Moreau
- CRCINA, SIRIC ILIAD, University Hospital of Nantes
- Elli Papaemmanuil
- Computational Oncology Service, Department of Epidemiology & Biostatistics, Center for Computational Oncology, Memorial Sloan Kettering Cancer Center
- Ludmil B. Alexandrov
- Department of Cellular and Molecular Medicine and Department of Bioengineering and Moores Cancer Center, University of California, La Jolla
- Xose S. Puente
- Unitat Hematopatologia, Hospital Clínic of Barcelona, Universitat de Barcelona
- Elias Campo
- Patologia Molecular de Neoplàsies Limfoides, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
- Reiner Siebert
- Institute of Human Genetics, Ulm University and Ulm University Medical Center
- Herve Avet-Loiseau
- IUC-Oncopole, and CRCT INSERM U1037
- Ola Landgren
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Nikhil Munshi
- Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Harvard Medical School
- Peter J. Campbell
- The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute
- Francesco Maura
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-020-15740-9
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
The initial mutational processes and how these lead to progression in multiple myeloma (MM) are unclear. Here, the authors identify mutational signatures that occur over time in a large cohort of MM patients and suggest features that may help in early diagnosis.
